L

Lonza ✓

Basel-headquartered CDMO, pharma contract manufacturing market leader.

Pharma & HealthZurich, Switzerland public Founded 1897 LONN
Website → Claim this page

At a Glance

Legal name
Lonza Group AG
Jurisdiction
Switzerland (Canton of Basel-Stadt)
Ownership
public
Listed on
SIX (LONN)
Employees
1000+
Revenue (est.)
$1B+
Headquarters
Muenchensteinerstrasse 38, 4002 Basel, Canton of Basel-Stadt, Switzerland
Snapshot Last updated 24 April 2026

# Lonza

Founded1897
Employees1000+
Revenue (est.)$1B+
OwnershipPublic LONN

Lonza

Lonza Group AG is the world's largest contract development and manufacturing organisation (CDMO) for the pharmaceutical and biotech industries, with roughly CHF 6.6 billion in 2024 revenue. The company manufactures active pharmaceutical ingredients (APIs), biologics (monoclonal antibodies, cell and gene therapies), and dosage forms for clients including Moderna, Roche, Pfizer, and most of the global top 20 pharma companies.

Founded in 1897 in Visp, Canton Valais, as an electrochemicals company, Lonza pivoted to fine chemicals in the post-war period and to pharmaceutical contract manufacturing in the 1990s. The modern group is Basel-headquartered, with its largest manufacturing sites at Visp (Switzerland), Portsmouth (New Hampshire), Singapore, and Nansha (China).

The listed entity Lonza Group AG is a Swiss Aktiengesellschaft registered in Canton Basel-Stadt and listed on SIX under ticker LONN. Lonza is a Swiss-only primary listing with an OTC ADR programme for US institutional access - the same structure as Nestle and Zurich Insurance.

  1. 1

    Tax strategy

    Lonza is the leading worked example of how Switzerland's regulatory, tax, and industrial-cluster stack supports contract pharmaceutical manufacturing at global scale. Three structural features explain why a CDMO of Lonza's size is Swiss-domiciled rather than Irish, Singaporean, or US-domiciled.

  2. 2

    Tax strategy

    First, the Swiss patent-box regime under TRAF (2020) reduces cantonal tax on income from qualifying patents and manufacturing processes to as low as 9-11% depending on canton. For a CDMO, a meaningful share of revenue is linked to manufacturing process patents and know-how that qualify for the patent box. Canton Basel-Stadt offers one of the more generous patent-box implementations among Swiss cantons, which is why Lonza has stayed in Basel rather than redomiciling to Zug (where the patent-box is similar but the pharma cluster is thinner).

  3. 3

    Estonia e-Residency play

    Second, Swissmedic (the Swiss drug regulator) and the EMA have a mutual recognition agreement that gives Swiss-licensed manufacturing sites direct access to EU markets without duplicate licensing. US FDA inspections at Swiss sites are also routine. A Swiss-headquartered CDMO carries regulatory friction close to zero across its three largest customer geographies. A Singapore or Irish CDMO must run additional regulatory overlays.

  4. 4

    Tax strategy

    Third, Basel-Stadt's labour pool is one of the deepest pharma-specific talent clusters globally. A new CDMO startup in Basel can hire process engineers, quality specialists, and regulatory affairs staff at scale in a way that is structurally impossible in Zug or Zurich. For Lonza's 19,000 employees, roughly a third sit in Visp and Basel, which keeps the company in Basel even though Zug offers lower headline tax rates.

Build Your Own

Replicate Lonza's structure in 4 steps

The formation playbook, distilled from how this company was actually set up.

1

Estonia e-Residency play

**Lonza Group AG** (Basel) - the listed Swiss Aktiengesellschaft, ticker LONN on SIX.

2

Estonia e-Residency play

**Lonza AG** (Basel) - the Swiss operating AG, holds Swiss manufacturing sites and group IP.

3

**Lonza Ltd** (Visp, Valais) - the main Swiss manufacturing

**Lonza Ltd** (Visp, Valais) - the main Swiss manufacturing entity, operates the Visp chemical and biologics complex.

4

Estonia e-Residency play

**Country subsidiaries** - Lonza Inc. (Delaware), Lonza Biologics Porrino S.L. (Spain), Lonza Biologics Tuas Pte. Ltd (Singapore), etc.

Use our formation guides
Switzerland Company Formation Switzerland Corporate Tax Switzerland Banking
Get a custom setup quote →

Comparable Companies

Novartis

Pharma & Health · Zurich, Switzerland

Roche

Pharma & Health · Zurich, Switzerland

Philips

Pharma & Health · Amsterdam, Netherlands

Sword Health

Pharma & Health · Lisbon, Portugal

Recent News & Filings

Frequently Asked Questions

What is a CDMO?

Contract Development and Manufacturing Organisation - a company that manufactures pharmaceutical products on behalf of other pharma and biotech companies under contract. Lonza is the largest CDMO globally.

Why is Lonza in Basel?

Swiss pharma cluster depth, proximity to Roche and Novartis as anchor customers, Swissmedic-EMA mutual recognition, and Basel-Stadt's patent-box-friendly tax regime. The combination is unmatched outside Ireland.

Does Lonza list on NYSE?

No. Lonza maintains a SIX-only primary listing (LONN) with OTC ADRs for US investors. Capital raising has historically been Swiss-franc debt and private placements rather than US equity issuance.

What happened with Moderna and Lonza?

Lonza manufactured mRNA-1273 (COVID-19 vaccine) for Moderna at the Visp facility under a multi-year contract signed in 2020. The contract has been partially wound down as vaccine demand normalised.

Sponsored Content Inquiries

Publish a long-form sponsored article about Lonza or your related business on Corpy. Editorial-style, SEO-optimized, linked from our country and industry hubs.

Start a sponsored article